PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

Slides:

Advertisements

Similar presentations

PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014.

Advertisements

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College.

Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

The potential and challenges of ARV-based HIV prevention: An overview

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

Pharmacist-Managed HIV Pre-Exposure Prophylaxis (PrEP) Clinic: Preliminary Outcomes From an Urban Community Health Clinic Mark T. Sawkin, PharmD, AAHIVP.

PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

PrEP Facts Clinical trials have shown daily oral Tenofovir to effectively prevent HIV acquisition PrEP must only be prescribed for HIV- patients and patients.

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

PRE-EXPOSURE PROPHYLAXIS in Pregnancy in South Africa

PrEP Scale Up in Kenya: Bridge to Scale Project

Regulatory Considerations for Approval: FDA perspective

PrEP for HIV Prevention

Efficacy and Safety of Medicines

A protocol in development IMPAACT Prevention Scientific Committee

On behalf of The MTN-020/ASPIRE Study Team

On Demand PrEP for Men at High Risk for HIV IPERGAY

Pre-exposure Prophylaxis (PrEP)

PrEP: A Case-by-Case Approach

HIV and the ART of Prevention

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

An Endocrinology Clinic in Dyslipidemia

Updates in Anticoagulation: What Did We Learn From ESC 2017?

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Program Goals Overview of HIV Epidemic HIV and Communities of Color.

The Possibilities of PrEP: Introduction

Stopping the Epidemic HIV Prevention Today

From Research to Rollout: Comparing oral PrEP and the dapivirine ring

Statin Selection in Special Patient Populations: A Case Challenge

Surveying the Safety of NOACs in the Real World

Translating Emerging HIV Data Into Clinical Practice

When Would You Use Single Inhaler Triple Therapy in COPD?

Are We Closer to Personalized Medicine in MS?

Efficacy and Safety of Edoxaban in Patients With AF and HF

PrEP Pre-Exposure Prophylaxis

Is RA Treatment Addressing the Real Needs of Patients?

Understanding PAD.

Initiating Pre-exposure Prophylaxis The PrEP Checklist

The cost-effectiveness of HIV pre-exposure prophylaxis in high-risk men who have sex with men and transgendered women in Brazil Paula M. Luz, Ben Osher,

A Better Solution For Cancer Patients With VTE?

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Extending Treatment for Thrombosis: What’s the Right Choice?

Advancing the Treatment of IBD With Biologics

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

Management of Systematic Lupus Erythematosus

PrEP Ongoing Care.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Factor Xa Inhibitors in PAD

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Updates in Anticoagulation: Key Sessions at ESC 2017

Program Goals Background: Anticoagulation in Patients With VTE.

Selecting Treatment Approaches in Hemophilia

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

PCSK9 Inhibitors and Statin Intolerance

Bob Holtkamp, Director of Prevention & Outreach

Presentation transcript:

Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice

PrEP Effectiveness

iPrEx Study A Closer Look at PrEP Efficacy in MSM

What Is PrEP?

Partners PrEP Study

iPrEx Study No Risk Compensation With PrEP

iPrEx Study Adverse Events

iPrEx Study Resistance

PrEP Safety Well Tolerated

PROUD Study PrEP Clinical Use

PROUD Study PrEP Is a High Impact Prevention Tactic

On-Demand PrEP IPERGAY Trial

On-Demand PrEP IPERGAY Trial (cont)

iPrEx Open Label Extension How Would PrEP Work in the Real World?

Patient Counseling

Serodiscordant Couples Treatment as Prevention

Ask the Right Questions to Determine Who Is at Risk

Bangkok Tenofovir Study Demonstrated Efficacy in IDU

Assessing Injection Drug Use

Essential Lab Tests for PrEP Candidates

CDC/WHO Clinically Eligible Patients

PrEP in Women Pharmacologic Measures of Exposure May Be Particularly Important

Summary

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)